Candel Therapeutics (CADL) TD Cowen 46th Annual Health Care Conference summary

Corporate and pipeline highlights

• Focus on viral immunotherapies for hard-to-treat solid tumors, with two main clinical candidates: CAN-2409 and CAN-3110.

• Stable financial position supported by recent debt, royalty, and equity deals.

• Led by an experienced team and advised by a renowned Research Advisory Board including Nobel laureates.

CAN-2409 program updates

• Positive pivotal phase III data in newly diagnosed localized prostate cancer, achieving primary and secondary endpoints under FDA SPA.

• Fast Track and RMAT designations granted by FDA; BLA submission planned for Q4 2024.

• Demonstrated significant improvement in disease-free survival and pathological complete response rates compared to placebo.

• Well-tolerated with minor flu-like symptoms, comparable to placebo.

• Additional exploratory data on metastasis and salvage therapy expected in Q2 2024.

CAN-3110 program updates

• Early-phase clinical trial in recurrent high-grade glioma shows doubling of median overall survival and cases of long-term remission.

• Unique oncolytic HSV design with tumor-specific replication, enabling strong immune response.

• Fast Track and Orphan Drug designations received; expansion into other nestin-expressing tumors considered.

• Pathological complete response reported; randomized controlled phase II trial in planning.

• Long-term survivor data to be announced in Q4 2024.